Research Analysts Offer Predictions for Evolus Q4 Earnings

Evolus, Inc. (NASDAQ:EOLS) – Research analysts at HC Wainwright reduced their Q4 2025 earnings per share estimates for shares of Evolus in a report released on Tuesday, February 3rd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.01 for the quarter, down from their prior forecast of $0.02. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $68.97 million for the quarter, compared to analysts’ expectations of $91.23 million.

A number of other equities analysts also recently issued reports on the stock. BTIG Research dropped their price objective on shares of Evolus from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Evolus from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Mizuho dropped their price target on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Monday, December 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Finally, Stifel Nicolaus decreased their target price on Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, January 13th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Evolus presently has an average rating of “Moderate Buy” and a consensus price target of $18.17.

Evolus Stock Performance

Shares of NASDAQ:EOLS opened at $4.70 on Wednesday. The stock’s 50-day simple moving average is $6.16 and its two-hundred day simple moving average is $6.76. The stock has a market capitalization of $304.65 million, a price-to-earnings ratio of -5.11 and a beta of 1.11. Evolus has a 52-week low of $4.56 and a 52-week high of $17.12.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC lifted its stake in Evolus by 17.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock worth $7,177,000 after purchasing an additional 172,846 shares in the last quarter. Pinnacle Associates Ltd. bought a new stake in shares of Evolus in the second quarter worth about $6,318,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Evolus in the second quarter worth about $22,431,000. Frontier Capital Management Co. LLC lifted its position in shares of Evolus by 37.9% in the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock worth $15,333,000 after buying an additional 457,533 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in Evolus during the second quarter valued at approximately $434,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider David Moatazedi sold 10,539 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the transaction, the insider owned 354,388 shares of the company’s stock, valued at $2,533,874.20. This represents a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.10% of the stock is currently owned by corporate insiders.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.